Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07099157 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Efficacy and Safety of Brivudine in the Treatment of Herpes Zoster

StatusRecruiting
PhasePhase 4
Started2025-08-25
View on ClinicalTrials.gov ↗

Amendment history

2025-12-28
Not Yet Recruiting→Recruiting Study Status, Oversight, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2025-09-01→confirmed 2025-08-25
Study sites4 entries, revised
AirPeking ForceUniversity MedicalThird Center, PLAHospital
2025-07-25
Original filing
This multicenter RCT aims to compare the efficacy and safety of Brivudine versus Famciclovir in treating acute herpes zoster. Primary objective: Evaluate pain reduction via Numeric Pain Rating Scale (NPRS) at Day 30. Secondary objectives: Compare NPRS at Day 3/Day 7/Day 14/Day 90, time to lesion resolution, Postherpetic Neuralgia (PHN) incidence, and safety.
Trial Details
NCT Number NCT07099157
Lead Sponsor Peking University Third Hospital
Collaborators: Peking University First Hospital, Air Force Military Medical University, China, Beijing Hospital of Traditional Chinese Medicine, Xuanwu Hospital, Beijing
Conditions Herpes Zoster
Enrollment 140 participants
Start Date 2025-08-25
Primary Completion 2026-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-01-02